1 option
Pharmacoeconomic review report Insulin degludec (Tresiba) (Novo Nordisk Canada Inc.) / Canadian Agency for Drugs and Technologies in Health.
- Format:
- Book
- Author/Creator:
- Canadian Agency for Drugs and Technologies in Health, author, issuing body.
- Language:
- English
- Subjects (All):
- Cost effectiveness.
- Outcome assessment (Medical care).
- Insulin.
- Diabetes.
- Physical Description:
- 1 online resource (40 pages) : illustrations
- Edition:
- First edition.
- Place of Publication:
- Canada : CADTH, 2017.
- Summary:
- Insulin degludec (Tresiba) is indicated for the treatment of adults with diabetes mellitus to improve glycemic control. The recommended daily starting dose of insulin degludec (IDeg) in type 2 diabetes mellitus (T2DM) patients who are insulin-naive is 10 units followed by individual dosage adjustments. In type 1 diabetes mellitus (T1DM) patients, IDeg is to be used once daily with mealtime insulin and requires subsequent individual dosage adjustments. IDeg is supplied in a 3 mL FlexTouch pen for subcutaneous administration at a submitted price of 125.28 per 1,500-unit pack.
- Notes:
- Description based on publisher supplied metadata and other sources.
The Penn Libraries is committed to describing library materials using current, accurate, and responsible language. If you discover outdated or inaccurate language, please fill out this feedback form to report it and suggest alternative language.